Dear Author,

Please check your proof carefully and mark all corrections at the appropriate place in the proof (e.g., by using on-screen annotation in the PDF file) or compile them in a separate list. To ensure fast publication of your paper please return your corrections within 48 hours.

For correction or revision of any artwork, please consult [http://www.elsevier.com/artworkinstructions](http://www.elsevier.com/artworkinstructions).

We were unable to process your file(s) fully electronically and have proceeded by

- [ ] Scanning (parts of) your article
- [ ] Rekeying (parts of) your article
- [ ] Scanning the artwork

Any queries or remarks that have arisen during the processing of your manuscript are listed below and highlighted by flags in the proof. Click on the 'Q' link to go to the location in the proof.

<table>
<thead>
<tr>
<th>Location in article</th>
<th>Query / Remark: click on the Q link to go Please insert your reply or correction at the corresponding line in the proof</th>
</tr>
</thead>
<tbody>
<tr>
<td>Q1</td>
<td>If there are any drug dosages in your article, please verify them and indicate that you have done so by initializing this query.</td>
</tr>
<tr>
<td>Q2</td>
<td>Please confirm that given names and surnames have been identified correctly and are presented in the desired order.</td>
</tr>
<tr>
<td>Q3</td>
<td>Confirm that addition of the Funding statement is correct.</td>
</tr>
<tr>
<td>Q4</td>
<td>Confirm that the conflicts of interest statement added to the article is correct.</td>
</tr>
<tr>
<td>Q5</td>
<td>OK to expand CVC in the title per journal style?</td>
</tr>
<tr>
<td>Q6</td>
<td>Can number “ISRCTN26577745” be deleted from the title and instead as a footnote? Please advise.</td>
</tr>
<tr>
<td>Q7</td>
<td>Bachelor's degrees are not usually listed in the author byline if higher degrees are available. Degrees have been removed. Please confirm that all changes made are OK.</td>
</tr>
<tr>
<td>Q8</td>
<td>Confirm that author affiliations are correct.</td>
</tr>
<tr>
<td>Q9</td>
<td>The Web site in reference 5 is faulty. Please provide the correct Web address.</td>
</tr>
<tr>
<td></td>
<td>Confirm the heading added to column 1 of table 1 is correct.</td>
</tr>
</tbody>
</table>

Please check this box or indicate your approval if you have no corrections to make to the PDF file.

Thank you for your assistance.
Highlights

- There is a lack of trial evidence directly comparing 2% chlorhexidine gluconate (CHG) in alcohol with other CHG solutions for the prevention of central venous catheter-related infections in hemodialysis patients.
- Although not statistically significant, there is a possible benefit from 2% chlorhexidine gluconate (CHG) in alcohol compared with routinely used CHG solutions.
- Findings add to the evidence base and can be used in future meta-analyses of similar studies.
Is 2% chlorhexidine gluconate in 70% isopropyl alcohol more effective at preventing central venous catheter–related infections than routinely used chlorhexidine gluconate solutions: A pilot multicenter randomized trial (ISRCTN26577745)?

Margaret McCann MSc, FFNMRCSI, PhD a,*, Fidelma Fitzpatrick MSc, FRCPI, FRCPath b,*, George Clarke MSc, MB a,d, Michael Clarke MD, FRCPI, FRCPath a,e

* School of Nursing and Midwifery, Trinity College Dublin, Dublin, Ireland
b Department of Clinical Microbiology, Royal College of Surgeons in Ireland, Dublin, Ireland
c Department of Microbiology, Beaumont Hospital, Dublin, Ireland
d Trinity Kidney Health Centre, Tallaght Hospital, Dublin, Ireland
e Northern Ireland Network for Trials Methodology Research, Queen’s University Belfast, Belfast, UK

Key Words:
Hemodialysis
central venous catheters
chlorhexidine gluconate
skin cleansing
infection prevention
clinical trial

Central venous catheter (CVC)–related infections impact negatively on hemodialysis patients’ quality of life.1,2 Effective preventive strategies include chlorhexidine gluconate (CHG) containing antiseptic solutions that minimize contamination of the CVC exit site and catheter hubs. There is a lack of trial evidence directly comparing 2% CHG in alcohol with other CHG solutions.3

To our knowledge, this is the first trial to evaluate 2% CHG in 70% isopropyl alcohol solution versus routine CHG solution for reducing CVC-related infections in hemodialysis patients.

METHODS
This pragmatic pilot randomized open-label trial took place at 3 outpatient hemodialysis units in Ireland from October 2010-October 2012. Patients were eligible if they were aged >18 years and on long-term hemodialysis using a permanent tunneled cuffed CVC inserted at least 4 weeks before trial entry. Exclusion criteria included unable to give informed consent, CVC used for purposes other than access for hemodialysis, known allergy to the interventions, CVC material not compatible with the interventions, using CVCs or dressings that were not standard practice for the unit, and patients unable to adhere to the trial protocol. A telephone randomization service used computer-generated stratified allocation sequences to allocate intervention and comparator solutions. Approval was granted by the Irish Medicine Board (CT 900/493/1) and the Institute Research Ethics Committee (REC 2010/27/03). Trial interventions included Chloraprep with Tint (CareFusion, San Diego, CA) for exit site cleansing and Sani-Cloth CHG 2% medical device wipes (PDI Healthcare, New York, NY) for catheter hub cleansing. Comparator participants received the routine CHG antiseptic agent for their dialysis facility: 0.5% CHG in 70% alcohol (Hydrex Pink, ECOLAB, Swindon, UK) or 0.05% aqueous CHG (Sterets [Unisept solution]; Medlock Medical, Oldham, UK). The frequency of the CVC dressing change was patient dependent.

The primary outcomes were CVC-related infection encompassing catheter-related bloodstream infection (CRBSI),4 catheter line–associated bloodstream infection (CLABSI),5 and local access infection.6 An independent microbiologist confirmed the outcome assessment blind to patient allocation.

Using intention-to-treat analysis, participants were followed-up to trial completion (12 months), primary outcome, or death and
analyzed in accordance with their random allocation. Statistical tests were 2-tailed, with \( P < 0.05 \) considered statistically significant. Analyses included frequencies (numbers of participants with an event and percentages) and \( \chi^2 \) or Fisher exact tests. The 2-sample independent \( t \) test and Mann-Whitney \( U \) test were used to estimate differences in group means.

**RESULTS**

Of the 201 patients with CVCs, 149 were eligible and 105 gave their consent to enter the trial. After randomization, 53 participants were assigned to the intervention and 52 to the comparator solution for their research site (0.5% CHG in alcohol [n = 42] or 0.05% aqueous CHG [n = 10]). Baseline characteristics are outlined in Table 1.

There were fewer catheter-related infections in the intervention group (n = 5/53, 9%) than in the comparator group (n = 10/52, 19%); this difference was not statistically significant (relative risk [RR], 0.49; 95% confidence interval [CI], 0.18–1.34; \( P = 0.15 \)). The intervention solution, 2% CHG in alcohol, did not significantly reduce CRBSI (RR, 0.49; 95% CI, 0.05–5.25; \( P = 0.55 \)), CLABSI (RR, 0.25; 95% CI, 0.03–2.12; \( P = 0.16 \)), or local access infection (RR, 0.74; 95% CI, 0.17–3.13; \( P = 0.68 \)) compared with the comparator solution.

In subcomparison analyses, 2% CHG in alcohol did not significantly reduce CRBSI (0/42 vs 2/42; RR, 0.20; 95% CI, 0.01–4.04; \( P = 0.15 \)), CLABSI (1/42 vs 2/42; RR, 0.50; 95% CI, 0.05–5.31; \( P = 0.56 \)), or local access infection (3/42 vs 4/42; RR, 0.75; 95% CI, 0.18–3.15; \( P = 0.70 \)) compared with 0.5% CHG in alcohol. When compared with 0.05% aqueous CHG (n = 10), the differences for CRBSI (1/11 [9%] vs 0/10; RR, 2.75; 95% CI, 0.12–60.7; \( P = 0.33 \)) and CLABSI (0/11 vs 2/10 [20%]; RR, 0.18; 95% CI, 0.01–3.41; \( P = 0.12 \)) were not statistically significant.

Four (7%) participants (all treated with 2% CHG in alcohol) experienced a skin sensitivity reaction (\( \chi^2 = 4.08, P = 0.04 \); Fisher exact test: \( P = 0.12 \)).

**DISCUSSION**

There was no clear difference between 2% CHG in alcohol and other routine CHG antiseptic solutions used in CVC exit site and catheter hub care in the prevention of CVC-related infections in hemodialysis patients. Overall, 7% of participants experienced an adverse reaction (skin sensitivity) to the 2% CHG in alcohol solution, and it is possible that participants reacted to the food dye this contains rather than to the CHG.

A limitation of our pilot randomized trial is the relatively small sample size, which was insufficient to detect clinically relevant differences in catheter-related infections between the intervention and comparator solutions. However, this is a large sample for an Irish hemodialysis study, with the at risk population studied being all hemodialysis patients in a catchment area of 1 million people, of whom 50% were recruited. A chance imbalance at randomization caused the comparator group to have a significantly higher use of trisodium citrate CVC lock solution than the intervention group, but a meta-analysis of CVC antimicrobial and nonantibiotic lock solutions showed no significant effect on catheter-related infection in patients using trisodium citrate only.4 The pragmatic nature of our study meant that we compared the trial intervention with what was used routinely for outpatients in hemodialysis units in Ireland; therefore, comparator participants were allocated different strengths and volumes of CHG.

**CONCLUSIONS**

Our trial investigating the effectiveness of 2% CHG in 70% alcohol versus other routinely used CHG solutions in the prevention of CVC-related infections appears to be the first such comparison in hemodialysis patients.

Although not statistically significant, the results suggest a possible benefit from 2% CHG in alcohol compared with routinely used CHG solutions. Although we cannot draw firm conclusions for practice from this pilot trial, our findings add to the evidence base and can be used in future meta-analyses of similar studies.

**Acknowledgments**

We thank the dialysis units and the patients who took part in this randomized trial. We also thank CareFusion and PDI Healthcare for providing the investigational medicinal products free of charge. We also thank Simon-Noble Clarke (CareFusion) and Ron Tierney (PDI Healthcare) for their help.

**References**


